Folberg Robert, Leach Lu, Valyi-Nagy Klara, Lin Amy Y, Apushkin Marsha A, Ai Zhuming, Barak Vivian, Majumdar Dibyen, Pe'er Jacob, Maniotis Andrew J
Department of Pathology, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
Invest Ophthalmol Vis Sci. 2007 Jul;48(7):2967-74. doi: 10.1167/iovs.06-1522.
To model the behavior of uveal melanoma in the liver.
A 15-muL suspension of metastatic MUM2B or either primary OCM1 or M619 uveal melanoma cells was injected into the liver parenchyma of 105 CB17 SCID mice through a 1-cm abdominal incision. Animals were killed at 2, 4, 6, or 8 weeks after injection. Before euthanatization, 3% FITC-BSA buffer was injected into the retro-orbital plexus of one eye of three mice. Liver tissues were examined by light and fluorescence microscopy, and were stained with human anti-laminin. Vasculogenic mimicry patterns were reconstructed from serial laser scanning confocal microscopic stacks.
OCM1a cells formed microscopic nodules in the mouse liver within 2 weeks after injection and metastasized to the lung 6 weeks later. By contrast, M619 and MUM2B cells formed expansile nodules in the liver within 2 weeks and gave rise to pulmonary metastases within 4 weeks after injection. Vasculogenic mimicry patterns, composed of human laminin and identical with those in human primary and metastatic uveal melanomas, were detected in the animal model. The detection of human rather than mouse laminin in the vasculogenic mimicry patterns in this model demonstrates that these patterns were of tumor cell origin and were not co-opted from the mouse liver microenvironment.
There are currently no effective treatments for metastatic uveal melanoma. This direct-injection model focuses on critical interactions between the tumor cell and the liver. It provides for translationally relevant approaches to the development of new modalities to detect small tumor burdens in patients, to study the biology of clinical dormancy of metastatic disease in uveal melanoma, to design and test novel treatments to prevent the emergence of clinically manifest liver metastases after dormancy, and to treat established uveal melanoma metastases.
建立葡萄膜黑色素瘤在肝脏中的行为模型。
通过1厘米的腹部切口,将15微升转移性MUM2B或原发性OCM1或M619葡萄膜黑色素瘤细胞悬液注入105只CB17 SCID小鼠的肝实质。在注射后2、4、6或8周处死动物。在安乐死之前,将3%异硫氰酸荧光素标记的牛血清白蛋白缓冲液注入三只小鼠一只眼睛的眶后丛。对肝脏组织进行光镜和荧光显微镜检查,并用抗人层粘连蛋白染色。从连续的激光扫描共聚焦显微镜堆栈重建血管生成拟态模式。
OCM1a细胞在注射后2周内在小鼠肝脏中形成微小瘤结节,并在6周后转移至肺。相比之下,M619和MUM2B细胞在2周内在肝脏中形成扩展性瘤结节,并在注射后4周内发生肺转移。在动物模型中检测到由人层粘连蛋白组成且与人类原发性和转移性葡萄膜黑色素瘤中相同的血管生成拟态模式。在该模型的血管生成拟态模式中检测到的是人而非小鼠的层粘连蛋白,这表明这些模式起源于肿瘤细胞,并非从小鼠肝脏微环境中获取。
目前对于转移性葡萄膜黑色素瘤尚无有效治疗方法。这种直接注射模型关注肿瘤细胞与肝脏之间的关键相互作用。它为开发新方法提供了与转化相关的途径,以检测患者体内的小肿瘤负荷,研究葡萄膜黑色素瘤转移性疾病临床休眠的生物学特性,设计和测试新的治疗方法以防止休眠后出现临床明显的肝转移,以及治疗已形成的葡萄膜黑色素瘤转移灶。